**Name of Journal: *World Journal of Stem Cells***

**Manuscript NO: 46727**

**Manuscript Type: REVIEW**

**Linking stemness with colorectal cancer initiation, progression, and therapy**

Iyer DN *et al.* Stem cells in colorectal cancer

**Deepak Narayanan Iyer, Wai-Yan Sin, Lui Ng**

**Deepak Narayanan Iyer, Wai-Yan Sin, Lui Ng,** Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

**ORCID number:** Deepak Narayanan Iyer (0000-0002-8050-6647); Wai-Yan Sin (0000-0003-2082-822X); Lui Ng (0000-0002-9010-2654).

**Author contributions:** Iyer DN, Sin WY and Ng L equally contributed to the literature review, as well as writing, editing, and revision of the manuscript, and approved the final version of the article to be published.

**Conflict-of-interest statement:** All the Authors have no conflict of interest related to the manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Lui Ng, PhD, Research Assistant Professor,** Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China. luing@hku.hk

**Telephone:** +852-3917-9817

**Received:** February 21, 2019

**Peer-review started:** February 22, 2019

**First decision:** June 3, 2019

**Revised:** June 12, 2019

**Accepted:** June 20, 2019

**Article in press:** June 20, 2019

**Published online:** August 26, 2019

**Abstract**

The discovery of cancer stem cells caused a paradigm shift in the concepts of origin and development of colorectal cancer. Several unresolved questions remain in this field though. Are colorectal cancer stem cells the cause or an effect of the disease? How do cancer stem cells assist in the spread of colorectal cancer to distant organs? What are the molecular or environmental factors affecting the roles of these cells in colorectal cancer? Through this review, we investigate the key findings until now and attempt to elucidate the origins, physical properties, microenvironmental niches, as well as the molecular signaling network that support the existence, self-renewal, plasticity, quiescence, and the overall maintenance of cancer stem cells in colorectal cancer. Increasing data show that the cancer stem cells play a crucial role not only in the establishment of the primary colorectal tumor but also in the distant spread of the disease. Hence, we will also look at the mechanisms adopted by cancer stem cells to influence the development of metastasis and evade therapeutic targeting and its role in the overall disease prognosis. Finally, we will illustrate the importance of understanding the biology of these cells to develop improved clinical strategies to tackle colorectal cancer.

**Key words:** Cancer stem cell; Colorectal cancer; Tumor microenvironment; Metastasis; Extracellular matrix; Tumor heterogeneity; Resistance; Stemness; Quiescence; Recurrence

© **The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** With the advancement of technology, the importance of deciphering the roles of stem cells in normal and malignant intestinal biology has grown tremendously. Aided by several molecular and environmental factors, evidence suggests that colorectal cancer stem cells exploit the intestinal cellular framework causing the development and spread of the disease, simultaneously promoting a poor prognosis through drug resistance and recurrence-based events. Only by a better understanding of the biology of these cells can there be an improvement in the strategies associated with clinical monitoring and therapeutic targeting required for disease management.

Iyer DN, Sin WY, Ng L. Linking stemness with colorectal cancer initiation, progression, and therapy. *World J Stem Cells* 2019; 11(8):519-534

URL: https://www.wjgnet.com/1948-0210/full/v11/i8/519.htm

DOI: https://dx.doi.org/10.4252/wjsc.v11.i8.519

**INTRODUCTION**

Colorectal cancer (CRC) is a heterogeneous disease. Approximately three decades ago, the genetic roadmap for the origin and development of CRC was identified[1]. Since then, massive technological progress has allowed the identification of numerous genetic and epigenetic components of the disease, further improving our understanding of the heterogeneity associated with CRC. We now know that not only does CRC exhibit a highly complex inter-tumor heterogeneity across multiple cases, warranting the need for personalized medicine[2], but it also displays a component of intra-tumor heterogeneity (morphological, genotypic, and phenotypic differences within the same tumor)[3]. The overall picture was further complicated by the discovery of cancer stem cells (CSCs) that led to an altered component of intra-tumor heterogeneity (*i.e*. heterogeneity between clonal populations), owing to the highly dynamic nature of CSCs. Major components affecting this behavior of CSCs include tumor genetics, epigenetic signals, and most importantly, the surrounding tumor microenvironment[4]. Notably, these factors have brought a landmark change in our understanding of the landscape of CRC development and progression. Considering these developments, here we review the current understanding as well as the evolving concepts of CSCs in the context of origin, development, and outcome of CRC. At the outset, we wish to clarify that the understanding of several aspects of CSCs, particularly within the field of CRC, is still at its infancy. Regardless, we aim to provide critical shreds of evidence from clinically relevant discoveries that would attempt to bridge, if not all, certain knowledge gaps existent within this field.

**THE STEM CELL NICHE: PERSPECTIVES OF THE ADULT INTESTINE**

An insight into the biology of intestinal stem cells (ISCs) will fuel our existing knowledge of the regulatory mechanisms of development and function of colorectal CSCs, owing to the similarities in several signaling pathways within normal and cancerous stem cells[5,6]. Structurally, the intestinal epithelium is organized into several finger-like villi protrusions extending into the gut lumen that is surrounded at the base by multiple glandular invaginations, the crypts of Lieberkühn, that extend into the extracellular matrix. The villus architecture comprises of non-dividing differentiated polyclonal cells with divergent functions of nutrient absorption-enterocytes, protective mucus barrier secretion - goblet cells, and gastrointestinal hormone secretion-enteroendocrine cells; all of which, including the post-mitotic Paneth cells that reside at the bottom of the crypt, are generated from the undifferentiated, rapidly proliferating multipotent stem cells residing as monoclonal compartments within the crypts. Unequivocally, the exorbitant rate of proliferation exhibited by the ISCs within the crypts is responsible for providing a high rate of self-renewal to the intestinal epithelium; essential to protect it by the persistent fusillade from physical, chemical, and/or biological insult[7].

Two functionally unique ISC populations are characterized within human and mice small intestine, the quiescent DNA label-retaining ISC (LRCs) identified at the +4 crypt position (characterized by the high expression of the polycomb complex protein Bmi1[8], homeodomain-containing protein Hopx[9], Tert[10], and Lrig1[11,12] markers), and the leucine-rich repeat–containing G protein-coupled receptor 5 (Lgr5+) expressing crypt base columnar cells (CBCs)[13]; both of which exhibit a self-renewal ability (self-renewal) as well as the potency to differentiate into cells of the intestinal epithelium (multi-potency), certifying them as true stem cells[7,14]. The identification of these ISC markers has been hugely possible through lineage tracing studies employing mouse models. Evidence from clonal analysis and knock-in experiments suggests that the Lgr5+ CBC cells represent the actively cycling stem cell niche that gives rise to daughter cells that are transferred into a transit amplifying (TA) compartment; subsequently dividing and moving towards the crypt-villus axis as differentiated cells, promoting intestinal homeostasis[13]. Contrastingly, the Lgr5- ISCs located on the +4 position of crypts are under 2% proliferative, and consequently serve as a reserve ISC pool that can assist the LRCs, directly or by regenerating the Lgr5+ cell population, in case of injury from chemotherapy or radiation to the functional stem cell population[8,15]. Indeed, through carefully derived genetic models, it has been shown that selective killing of Lgr5 cells can be restored by Lgr5–/Bmi1+ cells located anywhere in the crypt[16].

Muñoz *et al*[17] identified, however, that the Lgr5+ cells can also express the +4 markers; suggesting a high degree of plasticity between the two ISC populations. Furthermore, secretory precursors [including the Paneth cells, enteroendocrine cells, goblet cells, and Tuft cells (IL-25 secreting chemosensory cells that increase in numbers as a type-2 immune response)] derived from Lgr5+ cells expressing the Notch ligand DLL1, have also been shown to generate short-lived clones composed of differentiated secretory cells of intestinal epithelium, upon radiation-induced damage[18]. Yet another regenerative mechanism was identified by Barriga *et al*[19], who observed through single-cell transcriptomics, the existence of a subpopulation of Lgr5+ cells expressing an RNA-binding protein Mex3a that divides at a relatively slower rate, making it more resistant to radiation or chemotherapy-induced damage, and can help regenerate all intestinal lineages. To summarize, the small intestinal crypt functions as a well-defined network of interdependent cellular niches that serve as multiple layers of backups to ensure the smooth and continual functioning of the stem cell machinery to maintain intestinal homeostasis.

Within the ISC research community, while the small intestine has received a major focus, the colon stem cells lack significant characterization[5]. As compared to the small intestine, the colon shows large differences with the overall anatomy of the intestinal epithelium as well as the cellular architecture. The large intestine is devoid of any finger-like villi protrusions, or crypt based Bmi1+ cells, and Paneth cells[5]. The colonic stem cell niche has been characterized primarily with cells showing a high expression of Lgr5as well as ephrin type-B receptor 2, olfactomedin-4, and achaete-scute complex homolog-2 markers; which are capable of self-renewal and giving rise to the cells of the intestinal lineage[13,20-22]. Studies also indicate, however, the presence of slow-cycling colonic Lrig1+ cells that attempt to replenish the Lgr5 cell population upon injury[11]. Reports also show the presence of doublecortin-like kinase 1 cells within the colonic crypts that have been found to be actively proliferating in the presence of growth factors and give rise to intestinal lineage cells, forming enteroids[23,24]. Furthermore, unlike small intestine where the Paneth cells serve as the primary source of wingless/integrated (Wnt) signaling molecules that guide the renewal of the epithelium, recent work by Degirmenci *et al*[25] showed the existence of a group of subepithelial mesenchymal cells expressing zinc finger protein Gli1 that act as a critical source for Wnt secretion that directs colonic stem cell renewal. Moreover, the crypt structural elements, specifically the colonocytes, have also been found to yield a protective function to the proliferating cells within the crypt from potent metabolites produced by the intestinal microbiota[26]. Notwithstanding these crucial bits of research, a lot must be done to understand better the colonic crypt and the associated stem cell niche.

**ROLE OF INTESTINAL STEMNESS IN THE ORIGIN OF CRC**

The original model for colorectal carcinogenesis and progression, the “Vogelgram”, was laid down rather elaborately by Fearon and Vogelstein[1]. It provided a schematic in which loss of the adenomatous polyposis coli (*APC*) tumor suppressor gene would result in an adenoma and subsequently mutations in *KRAS*, *TP53*, phosphoinositide 3-kinase (*PI3K)*, and other genes would cause the development of a metastatic disease. A principal feature of CRC identified through this model was the monoclonal origin of the disease (*i.e*. CRC originates from the clonal expansion of one hyperproliferating cell). Importantly, the involvement of the crypt and the corresponding ISCs residing within them as CRC initiators were debated upon, since the analysis of several spontaneous adenomas found dysplastic cells with mutations in *APC* only on the luminal surface of the colon, while the underneath crypt and the ISCs were normal[27]. This finding caused the development of the ‘top-down’ model of tumor initiation that begins at the top of the crypt, in the intra-cryptal zones between crypt orifices, and then spreads laterally and downward, displacing the normal epithelium of crypts[27]. Though this was true for patients with familial adenomatous polyposis (FAP), immunohistochemical studies of early sporadic colorectal adenomas have shown proliferative adenomatous epithelium with nuclear beta-catenin within the entire crypt; pointing at the role of crypt based stem cells as progenitors of CRC[28]. In parallel, the Wright lab also examined the mucosa from FAP patients post-surgery and found that both sporadic and FAP adenomas originate as a uni-cryptal adenoma, with dysplastic lesions in a single but entire crypt, and grows ‘bottom-up’ by a division of the crypt at the base, termed as crypt fission. Although the lateral and downward spreading model was not completely excluded, several studies pointed out that crypt fission is the primary mode of adenoma progression in FAP[29,30] as well as sporadic adenomas[31]. Indeed, an alternative explanation for the top-down model was suggested by Shih *et al*[27] wherein the stem cells at the base of a single crypt develop the neoplasm, which subsequently transforms and migrates up the crypt and become a part of the superficial mucosae, which then spreads laterally and downward into adjacent crypts.

It has been shown in the past that the severity of intestinal cancer depends largely on the initiation than the progression, indicating the importance associated with the early events of CRC development[32,33]. Importantly, the identification of ISC specific expression markers has allowed for functional techniques that can be used to determine if they can function as progenitors of colorectal carcinogenesis. In 2007, O’Brien *et al*[34] characterized the first tumor stem cell marker, CD133, and pointed towards a CSC model of tumor initiation driven by CD133+ cells in CRC. A plethora of studies has indicated that specific deletion of *APC* in ISCs expressing Lgr5, LRIG1, or CD133 markers can induce rapid adenoma generation[11,35-37]. Moreover, activation of the β-catenin pathway within these cells as well as *BMI1*+ cells resulted in a similar outcome, indicating that ISCs are the primary cells of origin of CRC[8]. Mutations within key signaling pathways, including Wnt, Notch, and Hedgehog pathways, can dislodge the wild-type ISCs from the control of regulatory signals, allowing them to develop precursor lesions[38,39]. Most of these approaches, however, caused the generation of intestinal adenomas in mice that commonly occur in the small intestine and do not generally progress to carcinoma[40,41]. In contrast, human intestinal malignancies mostly occur in the colon. Additionally, the development of human CRC is also strongly dependent on environmental factors such as inflammatory conditions[42], which are lacking in genetic mouse models[5].

Owing to multiple differences between carcinogenesis in genetically modified mice and human patients, several studies have looked at the dynamics of stem cells in response to key genetic mutations and its influence on the development of CRC to improve our grasp on the actual mechanisms of CRC origin. Mutations within the intestine were assumed to arise due to several factors, including DNA replication errors and environmental factors such as carcinogen exposure, inflammation, *etc*. Since the TA cells represent the most actively proliferating population within the crypt, they are more prone to mutations; although given the short life span of these cells and the mild phenotype of the mutation, mutated TA cells offer a lower risk of serving as tumor initiators[43]. Indeed, it was shown that the wild-type ISC division follows the neutral drift principle to replace randomly any of the other crypt ISC populations[44,45]. Although oncogenic mutations aim towards preventing this, Vermeulen *et al*[46] and Snippert *et al*[47] suggest that the mutated cells can also be stochastically replaced by wild-type ISCs. What this means is that the likelihood of an inactivating mutation in a key tumor suppressor, like *APC*,to get fixed is less than 50%, making the mutated cell highly susceptible of getting lost in the continuous process of replacement[43]. Such a low probability makes CRC an extremely slow disease, postulated to take over a decade for cellular mutations to accumulate that could drive the initiation and progression of the malignancy[48]. Importantly, the presence of accompanying conditions such as intestinal inflammation tends to allow the mutated cells to prevail, pointing at the importance of environmental factors in conjunction with genetic factors in playing a critical role in CRC initiation[46]. Not surprisingly, while the competition exists between the normal and the mutated ISCs during the tumor initiation process, disease progression is associated with a rivalry between the CSCs, with stronger clones characterized by a larger number of accumulated mutations and resistance to environmental factors such as therapy[5].

In addition to a stem cell-based CRC origin model, a few studies have indicated the roles of differentiated cells in serving as the cell of origin for the disease. Like the ISC to colorectal CSC model, most of these studies also indicate that genetic events combined with environmental factors can favor the development of CRC. A loss of *APC* in the tuft cells accompanied by microenvironmental disturbances was found to induce colonic tumors[49]. Moreover, transgenic mice models have shown that intestinal epithelial cells can also dedifferentiate into tumor-initiating stem cells under the influence of enhanced Wnt and the inflammatory nuclear factor-kappa B (NFκB) signaling pathway[50]. Alternatively, accumulation of mutations such as *KRASG12D* that activates inflammatory signaling, accompanied with a loss of *APC* that results in the activation of Wnt pathway, yielded similar tumor initiation from the differentiated cells[50]. Taken together, the studies indicate that while CRC can have a stem cell (primary) or a non-stem cell (secondary) origin, the contributing factors include accumulation of mutations as well as environmental factors to confer a functional advantage for the development and progression of the tumor.

**INFLUENTIAL PATHWAYS REGULATING THE COLORECTAL CSCs**

There exists a molecular network surrounding the complex development of CSCs associated with CRC, and they are only recently emerging. Deciphering this network will not only improve our understanding of the role of stem cells in the origin and pathogenesis of CRC but rather will also provide better therapeutic avenues to deal with the malignancy. Although several signaling pathways have been implicated, notable ones that have been found to play crucial roles in the growth and functional maintenance of CSCs include the Wnt, Notch and Hedgehog, and the bone morphogenetic protein (BMP) pathways.

The canonical Wnt signaling pathway has been identified as a hallmark in the regulation of stem cells–from maintenance, proliferation, differentiation to apoptosis[51]. Under normal signaling, binding of the Wnt ligand to the transmembrane receptors tends to stabilize and allows the nuclear translocation of β-catenin causing transcriptional activation of important targets including *c-Myc*, *Axin2*, *Lgr5*, and *ASCL2* that govern stem cell fate, proliferation, as well as maintenance[52-56]. Specifically, within the intestine, active Wnt signaling is essential to maintain the stem cell niche within the crypt and promote gut homeostasis[57]. Intuitively, abnormal Wnt signaling has been implicated in several cancers, including CRC[58]. Inactivating mutations in *APC* and consequently a hyperactive Wnt signaling or activating mutations in β-catenin have been found in most of the CRC cases and has been identified as one of the initiating steps in tumor development[59]. In line with the ISC as the CRC cell of origin theory, Vermeulen *et al*[60]reported that CD133+ CRC cells growing as tumor spheres in culture contain a subpopulation of cells with constitutively high Wnt signaling. However, only a subset of these cells with the highest Wnt signaling was observed to show nuclear localization of β-catenin and behaved as CSCs. Denoted as the “β-catenin paradox”[61], the existence of intra-tumoral heterogeneity of Wnt signaling indicated that the pathogenesis of CSCs in CRC required contribution from other factors in addition to the loss of *APC*,such as *KRAS* mutations[62], PI3K[63], Notch[64] and Hedgehog signaling[65]. Moreover, mutations in essential Wnt pathway components, including the R-spondin/Lgr5/RNF43 module have been identified in almost 1/5th of CRC cases, which commonly co-occur with *APC* inactivation/deletion[66].

Importantly, Lgr5+ cells have been found to propagate CSCs within colon adenoma, and subsequently, Lgr5 has been identified as an important CSC marker[67]. More recently, studies have pointed out that while Lgr5- cells can revert into an Lgr5+ cell phenotype, allowing the development, maintenance, and metastasis of the growing tumor[68]; inhibition of Lgr5 strongly suppressed the growth of patient-derived tumor organoids[69]. These findings suggest that Lgr5+ CSCs are detrimental for the growth and propagation of CRC. Furthermore, Myant *et al*[70] show that following *APC* loss, the small GTPase RAC1 helps in the propagation of Lgr5+ CSCs in colon cancer by activating reactive oxygen species production, which activates NFκB signaling that promotes Wnt signaling. Co-activation of NFκB signaling and Wnt signaling has also been shown to promote colorectal tumorigenesis by causing dedifferentiation of intestinal cells into stem cells[50].

Cross-talk has also been observed between the Wnt signaling pathway and critical members of the Notch pathway. Like Wnt, Notch signaling is predominantly higher within the stem cell populations of the crypt and gradually decreases in the differentiated compartment, suggesting that Notch also contributes to ISC maintenance. An early study by the Clevers group[71] on ApcMin mice carrying a heterozygous mutation for *APC* that causes multiple intestinal neoplasia, identified a collaboration between active Notch signaling and Wnt pathway that is indispensable to maintain the proliferative adenoma cells. Moreover, suppression of Notch signals by deletion or by inhibition by a γ-secretase inhibitor resulted in an increase in the levels Math1, a basic helix-loop-helix transcriptional activator of cell differentiation in the intestine[72], consequently causing the arrest of cell proliferation within the crypt and the conversion of the crypt cells into differentiated secretory goblet cells[71]. it has been indicated, however, that goblet cells are commonly absent in CRC and show downregulated expression of Hath1, the human orthologue of Math1, suggesting an active Notch signaling in most CRC cases[73].

In contrast to the Wnt and the Notch pathways, the Hedgehog and BMP pathways are primarily active within the differentiated cells of the crypt. Although Hedgehog genes are commonly upregulated in CRC[74,75], numerous studies indicate that Gli-dependent canonical Hedgehog pathway antagonizes Wnt signaling promoting tumor cell differentiation[65,76,77]. This makes it difficult to treat CRC with drugs targeting members of the Hedgehog signaling since this strategy seemed to promote Wnt-based proliferation of CSCs[78,79]. However, recently, Regan *et al*[80] clarified that while the Gli-dependent Hedgehog signaling downregulates Wnt signaling, the non-canonical PTCH1-dependent Hedgehog signaling promotes Wnt signaling to allow the maintenance of CSCs in CRC. This breakthrough lets physicians target the two pathways (Hedgehog and Wnt) independently, allowing improved management of the disease.

Like Hedgehog, the transforming growth factor (TGF)-β/BMP pathway has been found to have diverse associations with the Wnt signaling network: From inhibition-to promoting cell differentiation and apoptosis[81] and to collaboration-to causing CRC tumorigenesis[82]. More recently, it was demonstrated that BMP signaling inhibits Lgr5 stem cell signature through a Wnt signaling independent mechanism by SMAD1/SMAD4 recruitment of histone deacetylase that blocks transcription of key factors essential to maintain the stemness of CSCs[83]. Indeed, germline mutations within the BMP receptor type I or its downstream effector SMAD4 have been shown to have a high risk of CRC[84,85]. Additionally, Whissell *et al*[86] reported a key role for the zinc-finger transcription factor GATA6, which was found to help maintain the Lgr5+ CSCs in adenoma, simultaneously suppressing BMP signaling by blocking the binding of β-catenin/TCF4 transcriptional complex to a regulatory region of the BMP4 locus within the differentiated tumor cells. *In vivo* knockdown of GATA6 was found to upregulate BMP signaling, suppressing CRC development.

Put together, these pathways offer a telescopic view of the multiple mechanisms of regulation of stem cells in the origin and development of CRC. Only by improving our understanding of these mechanisms of CSC regulation can we advance the therapeutic strategies required to deal with the progress of the disease.

**ROLE OF STEMNESS IN CRC METASTASIS**

Since stem cells have been implicated as the primary cell of origin of CRC, it is safe to assume that CSCs originating from ISCs would play a crucial role in the maintenance as well as the spread of the disease to distant sites. In 2010, our laboratory published the earliest account of a subpopulation of CD26+ CSCs from a primary CRC tumor responsible for the development of distant metastasis[87]. An important observation was the discovery of the ability of CD26+ CSCs isolated from the CRC tumor of a patient with liver metastasis to cause the formation of liver metastasis in mice, regardless of their CD133 or CD44 expression status. High expression of CD26 was also found to be associated with advanced tumor staging and poor overall survival of the patients[88]. While CSCs were considered as the key factors responsible for branching and spreading of the primary tumor, it was interesting to note that only small sub-populations of CSCs could initiate metastasis. Indeed, Brabletz *et al*[89] had deduced the existence of two subgroups of colorectal CSCs: The stationary CSCs that remain active within the primary tumor yet cannot disseminate to newer sites and the mobile CSCs that are derivatives of stationary CSCs and can form metastatic colonies. Importantly, for a CSC to be considered within the second group, the CSCs must have undergone epithelial-mesenchymal transition (EMT) to disseminate and form metastases while retaining its self-renewal capacity, heterogeneity acquired from the asymmetric division, as well as plasticity to adapt to the newer environment[89,90]. Moreover, a higher number of mobile CSCs at the tumor-host interface associated with the EMT phenotype has been found to correlate with an overall poor disease prognosis[91,92].

While distinct populations of CSCs initiated tumor progression, it was also essential to identify whether the same group of cells colonized target organs at random or through a tight-knit molecular pathway. Since the colorectal CSCs commonly enter the mesenteric circulation, metastasis is more commonly observed in the liver, followed by the lungs[93]. An elegant study by Gao and colleagues characterized CRC-specific migrating CSCs responsible for organ-specific metastasis[94]. The authors identified a specific group of CSCs expressing CD110, the thrombopoietin receptor that caused liver metastasis; considering that liver is the primary site for thrombopoietin production and hence serves as a chemotactic signal for the CD110+ CSCs. Furthermore, CSCs expressing CUB-domain-containing protein 1 could alone colonize the lungs by homing to the lung endothelial cells[94]. Thus, metastatic colonization not just depends on the existence of specific markers on the initiator cells but requires a specific complement of the target biological organ with prometastatic functions.

Although CSCs were hypothesized as the primary force for CRC progression and metastasis, it was not clear how this trait was orchestrated. What are the genetic or epigenetic or environmental mechanisms forcing the conversion of CSCs from tumor instigators to propagators? A crucial step towards malignancy is the induction of the EMT pathway–A fundamental process of embryonic development as well as cancer metastasis, characterized by the loss of the epithelial morphology and the accompanying markers simultaneously acquiring the mesenchymal phenotype. The process is primarily driven by the activation of a cohort of transcription factors, including snail, zinc-finger E-box binding factor, twist, and several others[95]. Accumulation of key genetic mutations and epigenetic changes in combination with an invasive environmental signal triggers the formation of migratory CSCs that show a high expression of genes critical for EMT as well as for maintaining the CSC phenotype, such as Slug, β-catenin, N-cadherin, as well as Lgr5, CD133, and CD44[90]. Importantly, Brabletz *et al*[89] suggested that microenvironmental alterations have a greater say over genetic factors in inducing EMT, since a reduction of these signals at the target site reverses the EMT pathway, allowing organ colonization. Indeed, the presence of pro-CSC microenvironmental cytokines, including, stromal cell-derived factor 1, osteopontin, and hepatocyte growth factor, promote the activation of PI3K and nuclear accumulation of β-catenin, causing a concomitant increase in the migratory metastatic CSC pool[96,97]. In fact, the pro-CSC cytokines are known to induce CSC plasticity by causing the dedifferentiation of tumor cells into a CSC phenotype that may subsequently adopt the metastatic CSC feature[60,97].

Another study identified the influence of tumor-associated macrophages secreted milk-fat globule-epidermal growth factor-VIII in conferring the CSC with a self-renewal and chemoresistance ability, by activating the Stat3 and Sonic Hedgehog pathways in CSC populations[98]. Contrarily, increase in the levels of the BMPs, a tumor suppressive cytokine, promotes CSC differentiation, inhibits the Wnt pathway by upregulating the phosphatase and tensin homolog and suppressing PI3K[99], and limits the expression of CD44v6; a diagnostic marker of metastatic CSCs[97]. Interestingly, the BMPs belong to the TGF-β superfamily and tend to inhibit tumor progression, while Todaro *et al*[97] suggest that TGF-β may contribute to the metastatic activity of CD44v6+ cells. Indeed, TGF-β serves as a key microenvironmental factor that plays dual roles, serving as a tumor suppressor during the early transformation phase and subsequently playing a pivotal role as an oncogene during the progression phase; a switch catalyzed by the accumulation of key mutations, such as p53[100] and SMAD4[101].

An early study by Calon *et al*[102] showed that the migratory CSCs ready for colonization can instruct the stroma of the host organ, by inducing an increase in the levels of TGF-β either *via* active secretion or, indirectly by the recruitment of macrophages, cancer-associated fibroblasts or platelets that produce TGF-β. Moreover, by activating the Smad proteins, specifically Smad2, Smad3, and Smad1/5/8, TGFβ1 has been shown to induce both EMT as well as stemness in CRC cells, leading to liver metastasis[103]. Additionally, a functional loss of Smad 4, a critical member of the TGF-β/Smad signaling, has been found to correlate with an increase in EMT signaling characterized by the loss of E-cadherin, leading to distant metastasis and overall poor patient prognosis[104-106]. Oncogenic TGF-β has been found to cooperate with a hyperactive Raf/mitogen-activated protein kinase pathway to cause an EMT phenotype[107]. Moreover, a collaboration between the loss of the epithelial E-cadherin protein and an increase in Wnt/β-catenin signaling, with an increased TGF-β release, allows cells to maintain the mesenchymal phenotype in the EMT process[108]. Following dissemination of the CSCs to the target organs, the new microenvironment is generally hostile towards the incoming tumor cells, which may affect the stemness as well as the survival of the cancer cells.

CSCs in CRC have been reported to suffer apoptosis almost immediately after reaching the liver[102]. Survival environmental signals in the form of cytokines and growth factors are hence generated by infiltrating cells from the primary tumor, along with the activation of stemness promoting Wnt as well as Notch pathways, to promote the creation of pre-metastatic niches within the target organs and improve the endurance of CRC based CSCs as well as allow colonization. A model of the role of stem cells in the normal colon, CRC development, as well as metastasis is shown in Figure 1.

**THE RELEVANCE OF STEMNESS IN CRC PROGNOSIS AND THERAPY**

Several factors affect the outcome in CRC—Including cancer spread (metastases), chemoresistance, and recurrence; all of these being mutually exclusive events. Moreover, numerous studies have pointed out a stronger involvement of CSCs, accompanied with our current inefficiency in understanding the biology of these cells in the malignancy, in allowing the factors to become dominant, leading to poor disease prognosis. Traditional therapy tends to debulk the tumor off the mature, differentiated cells, while the CSCs stay quiescent, and hence become resistant to drug or radio-therapy, allowing for improved opportunities to promote recurrence. An early report in this direction identified that the quiescence of CSCs can be attributed to an increased expression of ATP-binding cassette drug transporters, active DNA-repair machinery, as well as an innate resistance towards apoptotic cell death[109].

Furthermore, variants of key CSC associated markers including Lgr5, CD44, and aldehyde dehydrogenase 1A1 have been found to be associated with a shorter time to tumor recurrence in high-risk stage II and stage III CRC patients treated with fluoropyrimidine-based therapy; suggesting the association of the variants with improved survival and chemoresistance abilities of the CSCs[110]. It is important to realize that while traditional adjuvant fluoropyrimidine and/or platinum-based therapy has been found to be effective in CRC, exposure to these chemical agents may enrich a pool of CSCs responsible for resistance and recurrence. As proof of principle, the treatment of patients with unresectable CRC with mFOLFOX6 therapy was found to increase the levels of several CSC markers in distant metastases[111]. A previous study in this direction made use of cyclophosphamide or Irinotecan-based chemotherapy to treat xenogeneic CRC tumors and subsequently found an enrichment of a group of drug-resistant CSC populations with elevated levels of ALDH1 that could regenerate tumors[112].

While more aggressive CSCs tend to emerge in tumor development, it is the feature of plasticity that allows CSCs to pioneer resistance to therapy as well as recurrence. A study by Kobayashi *et al*[113] identified the interconversion of CSCs from a proliferative Lgr5+ state to a quiescent, drug-resistant Lgr5- state in the presence of an anticancer drug. Following reseeding and drug removal, the Lgr5- cells transitioned back to the Lgr5+ state, while maintaining the *in vivo* tumor-initiating properties all the time in both states. It is hence essential to identify and target key molecular factors that are common to multiple states of CSCs to achieve a better therapeutic cleanup in CRC. Indeed, by gene profiling studies the authors demonstrate that an epidermal growth factor receptor ligand, epiregulin, is expressed by both the Lgr5+ and Lgr5- states that could be targeted using an anti-epiregulin antibody[113]. Several reports have also indicated that the resistance and recurrence abilities of CSCs are strongly influenced by the tumor microenvironment as well as key signaling pathways and epigenetic modifications. Numerous cytokines and chemokines secreted by cancer-associated fibroblasts, particularly the MET receptor ligand hepatocyte growth factor, were found to promote CSC proliferation while making them resistant to apoptosis in response to epidermal growth factor receptor therapy[114]. Overactivation of Wnt signaling, a critical signaling network in the growth and development of stem cells, has been observed in 5-fluorouracil resistant CRC, while downregulation of Wnt transcription factor T cell factor 4 increases the sensitivity of the tumor to radiation therapy[115].

Recently, the role of microRNAs has also been identified as potent modulators of stem cell signaling within CRC. Notable ones include miR-15a and miR-16-1, which are frequently deleted in CRC cell lines as well as clinical specimens, are found to be associated with a greater number of B cells positive for immunoglobulin A (IgA+ B cells) and shorter survival periods[116]. At the molecular level, deletion/inhibition of miR-15a/miR-16-1 results in the upregulation of AP4, a c-Myc target[117], through a double negative feedback loop, resulting in distant metastases and poor survival[118]. MiR-15a has also been found to impact several other key genes implicated in the origin, maintenance, as well as chemoresistance of CSCs in CRC, including YAP1, doublecortin-like kinase 1, BMI1, and BCL2[119]. Similarly, the expression of miR-16-1 is negatively correlated with cyclooxygenase-2 level[120] which is also a downstream effector of the Wnt signaling pathway and thus has an active role in regulating the stem cell biology in CRC. Altogether, the miR-15a/miR-16-1 complex serves as a valuable therapeutic target to specifically tackle pathways associated with CSC maintenance in CRC.

Successful CRC targeting requires the inhibition of key pathways and environmental signals that function to promote the self-renewal ability, apoptotic resistance, stemness, as well as prolonged survival of the CSCs. Several potential CSC targeting drugs have been identified in the past several years, a few of which are under trials as well. Studies by Todaro *et al*[121,122] demonstrated a mechanism of apoptosis evasion by CD133+ CSCs by expressing IL-4, which could be neutralized by the treatment of the cells with an anti-IL4 antibody, IL-4DM. Moreover, silencing of the Aurora-A kinase, a critical regulator of mitosis, has been found to affect the colorectal CSCs by inhibiting proliferation, promoting the apoptotic potential, and sensitizing the cells to chemotherapy[123]. The role of mitochondrial targeting molecules as potential therapeutic agents has also been identified. A remarkable study by Colak *et al*[124] identified a role of BCLXL in protecting colon CSCs from chemotherapy, determined by decreased mitochondrial priming. By making use of BH3 mimetics, the authors successfully inhibit the BCL2 family members, sensitizing the CSCs to chemotherapy. Additionally, several molecules targeting critical members of Notch signaling[125,126] as well as the Wnt pathway[127] have been identified.

Although there are many more therapeutic targets as well as potential drugs under pre-clinical/clinical trials, understanding the clinical phenotype of the patient is critical to the usage of these drugs. Recent studies focusing on the development of CSC-targeting drugs advise upon the combined use of these drugs with the conventional adjuvant therapy to maximize the potential (Figure 2). The efficiency of CSC-targeting drugs is particularly higher on circulating CSCs due to the absence of a safe microenvironment as well as the presence of a toxic adjuvant therapy[5]. In advanced CRC, debulking of the tumor would not directly correspond to a similar loss of volume of the associated CSCs. In addition, in aggressive tumors, combination therapies increase the stress on tumor microenvironment, which has been known to contribute to an increase in the CSC pool. The situation is made further complex by the ability of CSCs and differentiated cells to interconvert. Strategies for monitoring the efficacy of CSC-targeting are still at infancy. Though several CSC markers have been identified in CRC, most of them are also expressed by ISCs. The success of CSC-targeting drugs hence strongly depends on the improvement of CSC monitoring techniques. Additionally, studying of patient-derived models of CRC is essential to increase our knowledge of the roles of CSCs and help piece the missing gaps within this field.

**CONCLUSION**

The landscape of CRC has progressed from a simple hierarchical model to a complex setup interspersed with multiple roles of dynamic CSCs that are modulated constantly by genetic, epigenetic, and specifically, microenvironmental factors. Although the discovery of CSCs in CRC was made roughly a decade ago, our understanding of the biology of these cells is still quite limited[34]. With the progress of technology, our existing knowledge of the complex roles and the dynamic nature of colonic stem cells, as well as CSCs, is undergoing constant evolution. However, better techniques for detection and isolation as well as the usage of patient-derived CRC models is essential to further our understanding of CSCs in CRC.

**REFERENCES**

1 **Fearon ER**, Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 1990; **61**: 759-767 [PMID: 2188735 DOI: 10.1016/0092-8674(90)90186-I]

2 **De Sousa E Melo F**, Vermeulen L, Fessler E, Medema JP. Cancer heterogeneity--a multifaceted view. *EMBO Rep* 2013; **14**: 686-695 [PMID: 23846313 DOI: 10.1038/embor.2013.92]

3 **Wersto RP**, Liblit RL, Deitch D, Koss LG. Variability in DNA measurements in multiple tumor samples of human colonic carcinoma. *Cancer* 1991; **67**: 106-115 [PMID: 1985705 DOI: 10.1002/1097-0142(19910101)67:1<106::AID-CNCR2820670120>3.0.CO;2-I]

4 **Kreso A**, Dick JE. Evolution of the cancer stem cell model. *Cell Stem Cell* 2014; **14**: 275-291 [PMID: 24607403 DOI: 10.1016/j.stem.2014.02.006]

5 **Zeuner A**, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: From the crypt to the clinic. *Cell Stem Cell* 2014; **15**: 692-705 [PMID: 25479747 DOI: 10.1016/j.stem.2014.11.012]

6 **Beck B**, Blanpain C. Unravelling cancer stem cell potential. *Nat Rev Cancer* 2013; **13**: 727-738 [PMID: 24060864 DOI: 10.1038/nrc3597]

7 **Barker N**, van Oudenaarden A, Clevers H. Identifying the stem cell of the intestinal crypt: Strategies and pitfalls. *Cell Stem Cell* 2012; **11**: 452-460 [PMID: 23040474 DOI: 10.1016/j.stem.2012.09.009]

8 **Sangiorgi E**, Capecchi MR. Bmi1 is expressed in vivo in intestinal stem cells. *Nat Genet* 2008; **40**: 915-920 [PMID: 18536716 DOI: 10.1038/ng.165]

9 **Takeda N**, Jain R, LeBoeuf MR, Wang Q, Lu MM, Epstein JA. Interconversion between intestinal stem cell populations in distinct niches. *Science* 2011; **334**: 1420-1424 [PMID: 22075725 DOI: 10.1126/science.1213214]

10 **Montgomery RK**, Carlone DL, Richmond CA, Farilla L, Kranendonk ME, Henderson DE, Baffour-Awuah NY, Ambruzs DM, Fogli LK, Algra S, Breault DT. Mouse telomerase reverse transcriptase (mTert) expression marks slowly cycling intestinal stem cells. *Proc Natl Acad Sci U S A* 2011; **108**: 179-184 [PMID: 21173232 DOI: 10.1073/pnas.1013004108]

11 **Powell AE**, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* 2012; **149**: 146-158 [PMID: 22464327 DOI: 10.1016/j.cell.2012.02.042]

12 **Wong VW**, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, van de Wetering M, Poulsom R, Wright NA, Trotter MW, Watt FM, Winton DJ, Clevers H, Jensen KB. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. *Nat Cell Biol* 2012; **14**: 401-408 [PMID: 22388892 DOI: 10.1038/ncb2464]

13 **Barker N**, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H, Peters PJ, Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. *Nature* 2007; **449**: 1003-1007 [PMID: 17934449 DOI: 10.1038/nature06196]

14 **Barker N**. Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. *Nat Rev Mol Cell Biol* 2014; **15**: 19-33 [PMID: 24326621 DOI: 10.1038/nrm3721]

15 **Yan KS**, Chia LA, Li X, Ootani A, Su J, Lee JY, Su N, Luo Y, Heilshorn SC, Amieva MR, Sangiorgi E, Capecchi MR, Kuo CJ. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. *Proc Natl Acad Sci U S A* 2012; **109**: 466-471 [PMID: 22190486 DOI: 10.1073/pnas.1118857109]

16 **Tian H**, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, de Sauvage FJ. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. *Nature* 2011; **478**: 255-259 [PMID: 21927002 DOI: 10.1038/nature10408]

17 **Muñoz J**, Stange DE, Schepers AG, van de Wetering M, Koo BK, Itzkovitz S, Volckmann R, Kung KS, Koster J, Radulescu S, Myant K, Versteeg R, Sansom OJ, van Es JH, Barker N, van Oudenaarden A, Mohammed S, Heck AJ, Clevers H. The Lgr5 intestinal stem cell signature: Robust expression of proposed quiescent '+4' cell markers. *EMBO J* 2012; **31**: 3079-3091 [PMID: 22692129 DOI: 10.1038/emboj.2012.166]

18 **van Es JH**, Sato T, van de Wetering M, Lyubimova A, Yee Nee AN, Gregorieff A, Sasaki N, Zeinstra L, van den Born M, Korving J, Martens ACM, Barker N, van Oudenaarden A, Clevers H. Dll1+ secretory progenitor cells revert to stem cells upon crypt damage. *Nat Cell Biol* 2012; **14**: 1099-1104 [PMID: 23000963 DOI: 10.1038/ncb2581]

19 **Barriga FM**, Montagni E, Mana M, Mendez-Lago M, Hernando-Momblona X, Sevillano M, Guillaumet-Adkins A, Rodriguez-Esteban G, Buczacki SJA, Gut M, Heyn H, Winton DJ, Yilmaz OH, Attolini CS, Gut I, Batlle E. Mex3a Marks a Slowly Dividing Subpopulation of Lgr5+ Intestinal Stem Cells. *Cell Stem Cell* 2017; **20**: 801-816.e7 [PMID: 28285904 DOI: 10.1016/j.stem.2017.02.007]

20 **Jung P**, Sato T, Merlos-Suárez A, Barriga FM, Iglesias M, Rossell D, Auer H, Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E. Isolation and in vitro expansion of human colonic stem cells. *Nat Med* 2011; **17**: 1225-1227 [PMID: 21892181 DOI: 10.1038/nm.2470]

21 **van der Flier LG**, van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van de Wetering M, Clevers H. Transcription factor achaete scute-like 2 controls intestinal stem cell fate. *Cell* 2009; **136**: 903-912 [PMID: 19269367 DOI: 10.1016/j.cell.2009.01.031]

22 **van der Flier LG**, Haegebarth A, Stange DE, van de Wetering M, Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. *Gastroenterology* 2009; **137**: 15-17 [PMID: 19450592 DOI: 10.1053/j.gastro.2009.05.035]

23 **Chandrakesan P**, May R, Qu D, Weygant N, Taylor VE, Li JD, Ali N, Sureban SM, Qante M, Wang TC, Bronze MS, Houchen CW. Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal. *Oncotarget* 2015; **6**: 30876-30886 [PMID: 26362399 DOI: 10.18632/oncotarget.5129]

24 **Sarkar S**, Swiercz R, Kantara C, Hajjar KA, Singh P. Annexin A2 mediates up-regulation of NF-κB, β-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. *Gastroenterology* 2011; **140**: 583-595.e4 [PMID: 20826156 DOI: 10.1053/j.gastro.2010.08.054]

25 **Degirmenci B**, Valenta T, Dimitrieva S, Hausmann G, Basler K. GLI1-expressing mesenchymal cells form the essential Wnt-secreting niche for colon stem cells. *Nature* 2018; **558**: 449-453 [PMID: 29875413 DOI: 10.1038/s41586-018-0190-3]

26 **Kaiko GE**, Ryu SH, Koues OI, Collins PL, Solnica-Krezel L, Pearce EJ, Pearce EL, Oltz EM, Stappenbeck TS. The Colonic Crypt Protects Stem Cells from Microbiota-Derived Metabolites. *Cell* 2016; **165**: 1708-1720 [PMID: 27264604 DOI: 10.1016/j.cell.2016.05.018]

27 **Shih IM**, Wang TL, Traverso G, Romans K, Hamilton SR, Ben-Sasson S, Kinzler KW, Vogelstein B. Top-down morphogenesis of colorectal tumors. *Proc Natl Acad Sci U S A* 2001; **98**: 2640-2645 [PMID: 11226292 DOI: 10.1073/pnas.051629398]

28 **Preston SL**, Wong WM, Chan AO, Poulsom R, Jeffery R, Goodlad RA, Mandir N, Elia G, Novelli M, Bodmer WF, Tomlinson IP, Wright NA. Bottom-up histogenesis of colorectal adenomas: Origin in the monocryptal adenoma and initial expansion by crypt fission. *Cancer Res* 2003; **63**: 3819-3825 [PMID: 12839979 DOI: 10.1097/00130404-200307000-00015]

29 **Wasan HS**, Park HS, Liu KC, Mandir NK, Winnett A, Sasieni P, Bodmer WF, Goodlad RA, Wright NA. APC in the regulation of intestinal crypt fission. *J Pathol* 1998; **185**: 246-255 [PMID: 9771477 DOI: 10.1002/(SICI)1096-9896(199807)185:3<246::AID-PATH90>3.0.CO;2-8]

30 **Chang WW**, Whitener CJ. Histogenesis of tubular adenomas in hereditary colonic adenomatous polyposis. *Arch Pathol Lab Med* 1989; **113**: 1042-1049 [PMID: 2774856 DOI: 10.1016/0264-410X(89)90186-2]

31 **Wong WM**, Mandir N, Goodlad RA, Wong BC, Garcia SB, Lam SK, Wright NA. Histogenesis of human colorectal adenomas and hyperplastic polyps: The role of cell proliferation and crypt fission. *Gut* 2002; **50**: 212-217 [PMID: 11788562 DOI: 10.1136/gut.50.2.212]

32 **Crabtree MD**, Tomlinson IP, Talbot IC, Phillips RK. Variability in the severity of colonic disease in familial adenomatous polyposis results from differences in tumour initiation rather than progression and depends relatively little on patient age. *Gut* 2001; **49**: 540-543 [PMID: 11559652 DOI: 10.1136/gut.49.4.540]

33 **Crabtree MD**, Tomlinson IP, Hodgson SV, Neale K, Phillips RK, Houlston RS. Explaining variation in familial adenomatous polyposis: Relationship between genotype and phenotype and evidence for modifier genes. *Gut* 2002; **51**: 420-423 [PMID: 12171967 DOI: 10.1136/gut.51.3.420]

34 **O'Brien CA**, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 2007; **445**: 106-110 [PMID: 17122772 DOI: 10.1038/nature05372]

35 **Barker N**, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature* 2009; **457**: 608-611 [PMID: 19092804 DOI: 10.1038/nature07602]

36 **Powell AE**, Vlacich G, Zhao ZY, McKinley ET, Washington MK, Manning HC, Coffey RJ. Inducible loss of one Apc allele in Lrig1-expressing progenitor cells results in multiple distal colonic tumors with features of familial adenomatous polyposis. *Am J Physiol Gastrointest Liver Physiol* 2014; **307**: G16-G23 [PMID: 24833705 DOI: 10.1152/ajpgi.00358.2013]

37 **Zhu L**, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. *Nature* 2009; **457**: 603-607 [PMID: 19092805 DOI: 10.1038/nature07589]

38 **Pardal R**, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. *Nat Rev Cancer* 2003; **3**: 895-902 [PMID: 14737120 DOI: 10.1038/nrc1232]

39 **Jordan CT**. Cancer stem cell biology: From leukemia to solid tumors. *Curr Opin Cell Biol* 2004; **16**: 708-712 [PMID: 15530785 DOI: 10.1016/j.ceb.2004.09.002]

40 **Su LK**, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. *Science* 1992; **256**: 668-670 [PMID: 1350108 DOI: 10.1126/science.1350108]

41 **Taketo MM**, Edelmann W. Mouse models of colon cancer. *Gastroenterology* 2009; **136**: 780-798 [PMID: 19263594 DOI: 10.1053/j.gastro.2008.12.049]

42 **Itzkowitz SH**, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. *Am J Physiol Gastrointest Liver Physiol* 2004; **287**: G7-17 [PMID: 15194558 DOI: 10.1152/ajpgi.00079.2004]

43 **Huels DJ**, Sansom OJ. Stem vs non-stem cell origin of colorectal cancer. *Br J Cancer* 2015; **113**: 1-5 [PMID: 26110974 DOI: 10.1038/bjc.2015.214]

44 **Lopez-Garcia C**, Klein AM, Simons BD, Winton DJ. Intestinal stem cell replacement follows a pattern of neutral drift. *Science* 2010; **330**: 822-825 [PMID: 20929733 DOI: 10.1126/science.1196236]

45 **Snippert HJ**, van der Flier LG, Sato T, van Es JH, van den Born M, Kroon-Veenboer C, Barker N, Klein AM, van Rheenen J, Simons BD, Clevers H. Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. *Cell* 2010; **143**: 134-144 [PMID: 20887898 DOI: 10.1016/j.cell.2010.09.016]

46 **Vermeulen L**, Snippert HJ. Stem cell dynamics in homeostasis and cancer of the intestine. *Nat Rev Cancer* 2014; **14**: 468-480 [PMID: 24920463 DOI: 10.1038/nrc3744]

47 **Snippert HJ**, Schepers AG, van Es JH, Simons BD, Clevers H. Biased competition between Lgr5 intestinal stem cells driven by oncogenic mutation induces clonal expansion. *EMBO Rep* 2014; **15**: 62-69 [PMID: 24355609 DOI: 10.1002/embr.201337799]

48 **Beerenwinkel N**, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. Genetic progression and the waiting time to cancer. *PLoS Comput Biol* 2007; **3**: e225 [PMID: 17997597 DOI: 10.1371/journal.pcbi.0030225]

49 **Westphalen CB**, Asfaha S, Hayakawa Y, Takemoto Y, Lukin DJ, Nuber AH, Brandtner A, Setlik W, Remotti H, Muley A, Chen X, May R, Houchen CW, Fox JG, Gershon MD, Quante M, Wang TC. Long-lived intestinal tuft cells serve as colon cancer-initiating cells. *J Clin Invest* 2014; **124**: 1283-1295 [PMID: 24487592 DOI: 10.1172/JCI73434]

50 **Schwitalla S**, Fingerle AA, Cammareri P, Nebelsiek T, Göktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, Rupec RA, Gerhard M, Schmid R, Barker N, Clevers H, Lang R, Neumann J, Kirchner T, Taketo MM, van den Brink GR, Sansom OJ, Arkan MC, Greten FR. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. *Cell* 2013; **152**: 25-38 [PMID: 23273993 DOI: 10.1016/j.cell.2012.12.012]

51 **Clevers H**. Wnt/beta-catenin signaling in development and disease. *Cell* 2006; **127**: 469-480 [PMID: 17081971 DOI: 10.1016/j.cell.2006.10.018]

52 **He TC**, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. *Science* 1998; **281**: 1509-1512 [PMID: 9727977 DOI: 10.1126/science.281.5382.1509]

53 **Tan SH**, Barker N. Stemming Colorectal Cancer Growth and Metastasis: HOXA5 Forces Cancer Stem Cells to Differentiate. *Cancer Cell* 2015; **28**: 683-685 [PMID: 26678334 DOI: 10.1016/j.ccell.2015.11.004]

54 **Jubb AM**, Chalasani S, Frantz GD, Smits R, Grabsch HI, Kavi V, Maughan NJ, Hillan KJ, Quirke P, Koeppen H. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. *Oncogene* 2006; **25**: 3445-3457 [PMID: 16568095 DOI: 10.1038/sj.onc.1209382]

55 **Lustig B**, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. *Mol Cell Biol* 2002; **22**: 1184-1193 [PMID: 11809809 DOI: 10.1128/MCB.22.4.1184-1193.2002]

56 **de Sousa EM**, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. *Clin Cancer Res* 2011; **17**: 647-653 [PMID: 21159886 DOI: 10.1158/1078-0432.CCR-10-1204]

57 **Gregorieff A**, Pinto D, Begthel H, Destrée O, Kielman M, Clevers H. Expression pattern of Wnt signaling components in the adult intestine. *Gastroenterology* 2005; **129**: 626-638 [PMID: 16083717 DOI: 10.1016/j.gastro.2005.06.007]

58 **Kinzler KW**, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. *Science* 1991; **253**: 661-665 [PMID: 1651562 DOI: 10.1126/science.1651562]

59 **Kinzler KW**, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996; **87**: 159-170 [PMID: 8861899 DOI: 10.1016/S0092-8674(00)81333-1]

60 **Vermeulen L**, De Sousa E Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. *Nat Cell Biol* 2010; **12**: 468-476 [PMID: 20418870 DOI: 10.1038/ncb2048]

61 **Fodde R**, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. *Curr Opin Cell Biol* 2007; **19**: 150-158 [PMID: 17306971 DOI: 10.1016/j.ceb.2007.02.007]

62 **Janssen KP**, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. *Gastroenterology* 2006; **131**: 1096-1109 [PMID: 17030180 DOI: 10.1053/j.gastro.2006.08.011]

63 **Vivanco I**, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nat Rev Cancer* 2002; **2**: 489-501 [PMID: 12094235 DOI: 10.1038/nrc839]

64 **Peignon G**, Durand A, Cacheux W, Ayrault O, Terris B, Laurent-Puig P, Shroyer NF, Van Seuningen I, Honjo T, Perret C, Romagnolo B. Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. *Gut* 2011; **60**: 166-176 [PMID: 21205878 DOI: 10.1136/gut.2009.204719]

65 **van den Brink GR**, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, Keller JJ, Nielsen C, Gaffield W, van Deventer SJ, Roberts DJ, Peppelenbosch MP. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. *Nat Genet* 2004; **36**: 277-282 [PMID: 14770182 DOI: 10.1038/ng1304]

66 **Giannakis M**, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs CS, Garraway LA. RNF43 is frequently mutated in colorectal and endometrial cancers. *Nat Genet* 2014; **46**: 1264-1266 [PMID: 25344691 DOI: 10.1038/ng.3127]

67 **Schepers AG**, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. *Science* 2012; **337**: 730-735 [PMID: 22855427 DOI: 10.1126/science.1224676]

68 **de Sousa e Melo F**, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, Anderson JE, Storm EE, Modrusan Z, Koeppen H, Dijkgraaf GJ, Piskol R, de Sauvage FJ. A distinct role for Lgr5<sup>+</sup> stem cells in primary and metastatic colon cancer. *Nature* 2017; **543**: 676-680 [PMID: 28358093 DOI: 10.1038/nature21713]

69 **Shimokawa M**, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, Date S, Sugimoto S, Kanai T, Sato T. Visualization and targeting of LGR5<sup>+</sup> human colon cancer stem cells. *Nature* 2017; **545**: 187-192 [PMID: 28355176 DOI: 10.1038/nature22081]

70 **Myant KB**, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, Schwitalla S, Kalna G, Ogg EL, Athineos D, Timpson P, Vidal M, Murray GI, Greten FR, Anderson KI, Sansom OJ. ROS production and NF-κB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. *Cell Stem Cell* 2013; **12**: 761-773 [PMID: 23665120 DOI: 10.1016/j.stem.2013.04.006]

71 **van Es JH**, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. *Nature* 2005; **435**: 959-963 [PMID: 15959515 DOI: 10.1038/nature03659]

72 **Yang Q**, Bermingham NA, Finegold MJ, Zoghbi HY. Requirement of Math1 for secretory cell lineage commitment in the mouse intestine. *Science* 2001; **294**: 2155-2158 [PMID: 11739954 DOI: 10.1126/science.1065718]

73 **Leow CC**, Romero MS, Ross S, Polakis P, Gao WQ. Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. *Cancer Res* 2004; **64**: 6050-6057 [PMID: 15342386 DOI: 10.1158/0008-5472.CAN-04-0290]

74 **Yoshikawa K**, Shimada M, Miyamoto H, Higashijima J, Miyatani T, Nishioka M, Kurita N, Iwata T, Uehara H. Sonic hedgehog relates to colorectal carcinogenesis. *J Gastroenterol* 2009; **44**: 1113-1117 [PMID: 19662327 DOI: 10.1007/s00535-009-0110-2]

75 **Oniscu A**, James RM, Morris RG, Bader S, Malcomson RD, Harrison DJ. Expression of Sonic hedgehog pathway genes is altered in colonic neoplasia. *J Pathol* 2004; **203**: 909-917 [PMID: 15258993 DOI: 10.1002/path.1591]

76 **Akiyoshi T**, Nakamura M, Koga K, Nakashima H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. *Gut* 2006; **55**: 991-999 [PMID: 16299030 DOI: 10.1136/gut.2005.080333]

77 **van Dop WA**, Uhmann A, Wijgerde M, Sleddens-Linkels E, Heijmans J, Offerhaus GJ, van den Bergh Weerman MA, Boeckxstaens GE, Hommes DW, Hardwick JC, Hahn H, van den Brink GR. Depletion of the colonic epithelial precursor cell compartment upon conditional activation of the hedgehog pathway. *Gastroenterology* 2009; **136**: 2195-2203.e1-7 [PMID: 19272384 DOI: 10.1053/j.gastro.2009.02.068]

78 **Berlin J**, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Clin Cancer Res* 2013; **19**: 258-267 [PMID: 23082002 DOI: 10.1158/1078-0432.CCR-12-1800]

79 **Catenacci DV**, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. *J Clin Oncol* 2015; **33**: 4284-4292 [PMID: 26527777 DOI: 10.1200/JCO.2015.62.8719]

80 **Regan JL**, Schumacher D, Staudte S, Steffen A, Haybaeck J, Keilholz U, Schweiger C, Golob-Schwarzl N, Mumberg D, Henderson D, Lehrach H, Regenbrecht CRA, Schäfer R, Lange M. Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells. *Cell Rep* 2017; **21**: 2813-2828 [PMID: 29212028 DOI: 10.1016/j.celrep.2017.11.025]

81 **He XC**, Zhang J, Tong WG, Tawfik O, Ross J, Scoville DH, Tian Q, Zeng X, He X, Wiedemann LM, Mishina Y, Li L. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 2004; **36**: 1117-1121 [PMID: 15378062 DOI: 10.1038/ng1430]

82 **Takaku K**, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. *Cell* 1998; **92**: 645-656 [PMID: 9506519 DOI: 10.1016/S0092-8674(00)81132-0]

83 **Qi Z**, Li Y, Zhao B, Xu C, Liu Y, Li H, Zhang B, Wang X, Yang X, Xie W, Li B, Han JJ, Chen YG. BMP restricts stemness of intestinal Lgr5<sup>+</sup> stem cells by directly suppressing their signature genes. *Nat Commun* 2017; **8**: 13824 [PMID: 28059064 DOI: 10.1038/ncomms13824]

84 **Howe JR**, Bair JL, Sayed MG, Anderson ME, Mitros FA, Petersen GM, Velculescu VE, Traverso G, Vogelstein B. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. *Nat Genet* 2001; **28**: 184-187 [PMID: 11381269 DOI: 10.1038/88919]

85 **Howe JR**, Roth S, Ringold JC, Summers RW, Järvinen HJ, Sistonen P, Tomlinson IP, Houlston RS, Bevan S, Mitros FA, Stone EM, Aaltonen LA. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. *Science* 1998; **280**: 1086-1088 [PMID: 9582123 DOI: 10.1126/science.280.5366.1086]

86 **Whissell G**, Montagni E, Martinelli P, Hernando-Momblona X, Sevillano M, Jung P, Cortina C, Calon A, Abuli A, Castells A, Castellvi-Bel S, Nacht AS, Sancho E, Stephan-Otto Attolini C, Vicent GP, Real FX, Batlle E. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. *Nat Cell Biol* 2014; **16**: 695-707 [PMID: 24952462 DOI: 10.1038/ncb2992]

87 **Pang R**, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, Tan VP, Yau TC, Poon RT, Wong BC. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. *Cell Stem Cell* 2010; **6**: 603-615 [PMID: 20569697 DOI: 10.1016/j.stem.2010.04.001]

88 **Lam CS**, Cheung AH, Wong SK, Wan TM, Ng L, Chow AK, Cheng NS, Pak RC, Li HS, Man JH, Yau TC, Lo OS, Poon JT, Pang RW, Law WL. Prognostic significance of CD26 in patients with colorectal cancer. *PLoS One* 2014; **9**: e98582 [PMID: 24870408 DOI: 10.1371/journal.pone.0098582]

89 **Brabletz T**, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: Migrating cancer stem cells - an integrated concept of malignant tumour progression. *Nat Rev Cancer* 2005; **5**: 744-749 [PMID: 16148886 DOI: 10.1038/nrc1694]

90 **Zhou Y**, Xia L, Wang H, Oyang L, Su M, Liu Q, Lin J, Tan S, Tian Y, Liao Q, Cao D. Cancer stem cells in progression of colorectal cancer. *Oncotarget* 2017; **9**: 33403-33415 [PMID: 30279970 DOI: 10.18632/oncotarget.23607]

91 **Ueno H**, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. *Histopathology* 2002; **40**: 127-132 [PMID: 11952856 DOI: 10.1046/j.1365-2559.2002.01324.x]

92 **Ueno H**, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC. A new prognostic staging system for rectal cancer. *Ann Surg* 2004; **240**: 832-839 [PMID: 15492565 DOI: 10.1097/01.sla.0000143243.81014.f2]

93 **Oskarsson T**, Batlle E, Massagué J. Metastatic stem cells: Sources, niches, and vital pathways. *Cell Stem Cell* 2014; **14**: 306-321 [PMID: 24607405 DOI: 10.1016/j.stem.2014.02.002]

94 **Gao W**, Chen L, Ma Z, Du Z, Zhao Z, Hu Z, Li Q. Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. *Gastroenterology* 2013; **145**: 636-46.e5 [PMID: 23747337 DOI: 10.1053/j.gastro.2013.05.049]

95 **Peinado H**, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? *Nat Rev Cancer* 2007; **7**: 415-428 [PMID: 17508028 DOI: 10.1038/nrc2131]

96 **Ormanns S**, Neumann J, Horst D, Kirchner T, Jung A. WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling. *Oncotarget* 2014; **5**: 2999-3011 [PMID: 24930890 DOI: 10.18632/oncotarget.1626]

97 **Todaro M**, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S, Cocorullo G, Gulotta G, Dieli F, De Maria R, Stassi G. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. *Cell Stem Cell* 2014; **14**: 342-356 [PMID: 24607406 DOI: 10.1016/j.stem.2014.01.009]

98 **Jinushi M**, Chiba S, Yoshiyama H, Masutomi K, Kinoshita I, Dosaka-Akita H, Yagita H, Takaoka A, Tahara H. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. *Proc Natl Acad Sci U S A* 2011; **108**: 12425-12430 [PMID: 21746895 DOI: 10.1073/pnas.1106645108]

99 **Lombardo Y**, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, Gulotta G, Dieli F, de Maria R, Stassi G. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. *Gastroenterology* 2011; **140**: 297-309 [PMID: 20951698 DOI: 10.1053/j.gastro.2010.10.005]

100 **Adorno M**, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, Parenti AR, Rosato A, Bicciato S, Balmain A, Piccolo S. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. *Cell* 2009; **137**: 87-98 [PMID: 19345189 DOI: 10.1016/j.cell.2009.01.039]

101 **Zhang B**, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, Datta PK. Antimetastatic role of Smad4 signaling in colorectal cancer. *Gastroenterology* 2010; **138**: 969-80.e1-3 [PMID: 19909744 DOI: 10.1053/j.gastro.2009.11.004]

102 **Calon A**, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV, Sevillano M, Nadal C, Jung P, Zhang XH, Byrom D, Riera A, Rossell D, Mangues R, Massagué J, Sancho E, Batlle E. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. *Cancer Cell* 2012; **22**: 571-584 [PMID: 23153532 DOI: 10.1016/j.ccr.2012.08.013]

103 **Zubeldia IG**, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J, Calvo A. Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1-targeting peptides P17 and P144. *Exp Cell Res* 2013; **319**: 12-22 [PMID: 23153552 DOI: 10.1016/j.yexcr.2012.11.004]

104 **Reinacher-Schick A**, Baldus SE, Romdhana B, Landsberg S, Zapatka M, Mönig SP, Hölscher AH, Dienes HP, Schmiegel W, Schwarte-Waldhoff I. Loss of Smad4 correlates with loss of the invasion suppressor E-cadherin in advanced colorectal carcinomas. *J Pathol* 2004; **202**: 412-420 [PMID: 15095268 DOI: 10.1002/path.1516]

105 **Miyaki M**, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, Mori T. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. *Oncogene* 1999; **18**: 3098-3103 [PMID: 10340381 DOI: 10.1038/sj.onc.1202642]

106 **Alazzouzi H**, Alhopuro P, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Hemminki A, Schwartz S Jr, Aaltonen LA, Arango D. SMAD4 as a prognostic marker in colorectal cancer. *Clin Cancer Res* 2005; **11**: 2606-2611 [PMID: 15814640 DOI: 10.1158/1078-0432.CCR-04-1458]

107 **Janda E**, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J, Beug H, Grünert S. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: Dissection of Ras signaling pathways. *J Cell Biol* 2002; **156**: 299-313 [PMID: 11790801 DOI: 10.1083/jcb.200109037]

108 **Eger A**, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, Beug H, Foisner R. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. *Oncogene* 2004; **23**: 2672-2680 [PMID: 14755243 DOI: 10.1038/sj.onc.1207416]

109 **Dean M**, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer* 2005; **5**: 275-284 [PMID: 15803154 DOI: 10.1038/nrc1590]

110 **Gerger A**, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. *Clin Cancer Res* 2011; **17**: 6934-6943 [PMID: 21918173 DOI: 10.1158/1078-0432.CCR-11-1180]

111 **Tsuji S**, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. *Br J Cancer* 2012; **106**: 126-132 [PMID: 22095227 DOI: 10.1038/bjc.2011.505]

112 **Dylla SJ**, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, Clarke MF, Hoey T, Lewicki J, Gurney AL. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. *PLoS One* 2008; **3**: e2428 [PMID: 18560594 DOI: 10.1371/journal.pone.0002428]

113 **Kobayashi S**, Yamada-Okabe H, Suzuki M, Natori O, Kato A, Matsubara K, Jau Chen Y, Yamazaki M, Funahashi S, Yoshida K, Hashimoto E, Watanabe Y, Mutoh H, Ashihara M, Kato C, Watanabe T, Yoshikubo T, Tamaoki N, Ochiya T, Kuroda M, Levine AJ, Yamazaki T. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. *Stem Cells* 2012; **30**: 2631-2644 [PMID: 23081779 DOI: 10.1002/stem.1257]

114 **Luraghi P**, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. *Cancer Res* 2014; **74**: 1857-1869 [PMID: 24448239 DOI: 10.1158/0008-5472.CAN-13-2340-T]

115 **Kendziorra E**, Ahlborn K, Spitzner M, Rave-Fränk M, Emons G, Gaedcke J, Kramer F, Wolff HA, Becker H, Beissbarth T, Ebner R, Ghadimi BM, Pukrop T, Ried T, Grade M. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. *Carcinogenesis* 2011; **32**: 1824-1831 [PMID: 21983179 DOI: 10.1093/carcin/bgr222]

116 **Liu R**, Lu Z, Gu J, Liu J, Huang E, Liu X, Wang L, Yang J, Deng Y, Qian J, Luo F, Wang Z, Zhang H, Jiang X, Zhang D, Qian J, Liu G, Zhu H, Qian Y, Liu Z, Chu Y. MicroRNAs 15A and 16-1 Activate Signaling Pathways That Mediate Chemotaxis of Immune Regulatory B cells to Colorectal Tumors. *Gastroenterology* 2018; **154**: 637-651.e7 [PMID: 29031499 DOI: 10.1053/j.gastro.2017.09.045]

117 **Jung P**, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. *Proc Natl Acad Sci U S A* 2008; **105**: 15046-15051 [PMID: 18818310 DOI: 10.1073/pnas.0801773105]

118 **Shi L**, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. *Cancer Res* 2014; **74**: 532-542 [PMID: 24285725 DOI: 10.1158/0008-5472.CAN-13-2203]

119 **Fesler A**, Liu H, Ju J. Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1. *Oncotarget* 2017; **9**: 2367-2383 [PMID: 29416778 DOI: 10.18632/oncotarget.23414]

120 **Young LE**, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. *Mol Cancer Res* 2012; **10**: 167-180 [PMID: 22049153 DOI: 10.1158/1541-7786.MCR-11-0337]

121 **Todaro M**, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. *Cell Stem Cell* 2007; **1**: 389-402 [PMID: 18371377 DOI: 10.1016/j.stem.2007.08.001]

122 **Todaro M**, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. *Cell Cycle* 2008; **7**: 309-313 [PMID: 18235245 DOI: 10.4161/cc.7.3.5389]

123 **Cammareri P**, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. *Cancer Res* 2010; **70**: 4655-4665 [PMID: 20460511 DOI: 10.1158/0008-5472.CAN-09-3953]

124 **Colak S**, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, Letai A, Medema JP. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. *Cell Death Differ* 2014; **21**: 1170-1177 [PMID: 24682005 DOI: 10.1038/cdd.2014.37]

125 **Hoey T**, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, Fitch-Bruhns M, Lazetic S, Park IK, Sato A, Satyal S, Wang X, Clarke MF, Lewicki J, Gurney A. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. *Cell Stem Cell* 2009; **5**: 168-177 [PMID: 19664991 DOI: 10.1016/j.stem.2009.05.019]

126 **Funahashi Y**, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, Suzuki A, Wang X, Shawber CJ, Kandel JJ, Yamashiro DJ, Kitajewski J. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. *Cancer Res* 2008; **68**: 4727-4735 [PMID: 18559519 DOI: 10.1158/0008-5472.CAN-07-6499]

127 **Krishnamurthy N**, Kurzrock R. Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. *Cancer Treat Rev* 2018; **62**: 50-60 [PMID: 29169144 DOI: 10.1016/j.ctrv.2017.11.002]

**P-Reviewer:** Corrales FJ, Yu B, Li SC **S-Editor:** Yan JP

**L-Editor:** Filipodia **E-Editor:** Xing YX

**Specialty type:** Cell and tissue engineering
**Country of origin:** China
**Peer-review report classification**
**Grade A (Excellent):** A
**Grade B (Very good):** B, B
**Grade C (Good):** 0
**Grade D (Fair):** 0 **Grade E (Poor):** 0

****

**Figure 1 Role of stem cells in normal colon and CRC.** Within the normal colon, ISCs constantly divide to give rise to the differentiated cells within the epithelium that have a multitude of functions. In colorectal cancer, the ISCs can develop into CSCs that lead to tumor formation. Moreover, the transient amplifying cells as well as the differentiated intestinal cells can mutate into mature tumor cells that can subsequently dedifferentiate to form CSCs. Owing to genetic, epigenetic or environmental signals, the stationary CSCs can transform into migratory CSCs that pass *via* circulation to target organs and colonize. Critical pathways and genetic events have been shown for the entire process of CRC tumorigenesis and progression. Moreover, key biomarkers have been shown for the ISCs and the CRC based CSCs, although there is some overlap in this panel. CRC: Colorectal cancer; CSC: Cancer stem cells; ISC: Intestinal stem cell; EMT: Epithelial mesenchymal transition; Wnt: Wingless/integrated; APC: Adenomatous polyposis coli; KRAS: Kirsten rat sarcoma viral oncogene homolog; BMP: Bone morphogenetic protein; TGF-β: Transforming growth factor-β; VEGF: Vascular endothelial growth factor; MMP: Matrix metalloproteinase.



**Figure 2 Therapeutic strategies in colorectal cancer.** Targeting the tumor bulk in colorectal cancer with adjuvant therapy leads to tumor regression, although CSCs may escape cell death. Such a chemoresistance event leads to tumor recurrence and overall poor prognosis. In contrast, treatment with a combination of adjuvant therapy and CSC-targeting therapy would also eradicate the CSC population, along with the tumor bulk. In the long term, reduction in CSC volume would kill the tumor. CSC: Cancer stem cells; ISC: Intestinal stem cells.